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Melatonin as a powerful antioxidant
Melatonin is a hormone that has many body functions 
and, for several decades, its antioxidant potential has 
been increasingly talked about. There is a relationship 
between failure in melatonin production in the pineal 
gland, an insufficient supply of this hormone to the body, 
and the occurrence of free radical etiology diseases such 
as neurodegenerative diseases, cardiovascular diseases, 
diabetes, cancer and others. Despite the development of 
molecular biology, numerous in vitro and in vivo studies, 
the exact mechanism of melatonin antioxidant activity is 
still unknown. Nowadays, the use of melatonin supple-
mentation is more and more common, not only to prevent 
insomnia, but also to slow down the aging process and 
provide protection against diseases. The aim of this study 
is to get acquainted with current reports on melatonin, 
antioxidative mechanisms and their importance in diseases 
of free radical etiology.
Keywords: melatonin, antioxidants, lipid peroxidation, 
free radicals, oxidative stress
INTRODUCTION
Melatonin (N-acetyl-5-methoxytryptamine), an indoleamine that was first isolated 
from pineal pinealocytes in 1958 by Lerner et al. (1), is named because of the effect it causes 
on the amphibian pigment found in the skin of amphibians and reptiles. It is suggested 
that melatonin is the oldest signal molecule on Earth. It occurs in vertebrates, inverte-
brates, bacteria, yeasts, plants, as well as in algae. In herbs used in Chinese medicine, its 
content varies from 10 to 4000 ng g–1 dry matter, which is why they were used to delay 
aging processes and to treat diseases with free radical etiology (2). It is synthesized mainly 
by the pineal gland but it is also produced by the digestive system, blood cells, lens and 
retina of the eye, kidneys, thyroid, ovaries, cerebellum, bile, bone marrow and cerebrospi-
nal fluid (2). The level of the hormone in the blood changes cyclically throughout the day 
since light inhibits the melatonin biosynthesis (1, 2). In addition, the concentration of 
 melatonin depends on season and age. Scientific research has shown that the production 
of extrapineal melatonin is not light-dependent (2). During the night, the concentration of 
melatonin in human plasma is high and amounts to ca 120 pg mL–1 while, during the day, 
it decreases significantly to the value of about 10 pg mL–1. The crossing of melatonin 
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through the placental barrier is one of the signal mechanisms that synchronize the moth-
er’s biological clock with the fetus’s. The circadian rhythm of melatonin occurs between 
the age of 6–9 weeks, whereas the distinct circadian rhythm is formed in the newborn 
within 3–4 months of life, after which its nocturnal level increases, reaching the highest 
values at the age of 3–6 years. Human infants’ melatonin levels become regular in about 
the third month after birth, with the highest levels measured between midnight and 8:00 
a.m. Stabilization of the hormone is visible at the age of 35–40. After the age of 40, the 
concentration of melatonin decreases, which may lead to disturbances in the proper body 
function. Due to the lipophilic structure, melatonin penetrates all biological barriers in the 
body and also interacts with several biochemical pathways and affects tissues and cells (2). 
This hormone is also found in human milk and according to Illnerova et al. (3) melatonin 
concentration is of the order of 99 ± 26 pmol L–1. Katzer et al. (4) compared the concentration 
of breast milk from night and day batches. Higher melatonin concentration was found in 
human milk at night (7.3 pg mL–1) than in the day (1.5 pg mL–1). It is assumed that melato-
nin circulating in the blood during the day comes from the gastrointestinal tract, where 
the content of this hormone is 400-fold higher than in the pineal gland, and the concentra-
tion 10–100 times higher than in the plasma (5). In contrast, the level of melatonin in the 
cerebrospinal fluid of the lateral ventricles is 5–10 times higher than in serum (5).
HOW DOES MELATONIN FUNCTION?
Melatonin works in a cell in four ways: by binding to membrane receptors, through 
interaction with nuclear receptors, through direct binding to cytoplasmic proteins and as 
an antioxidant (6). The main mechanism of action of melatonin is the interaction with 
melatonin receptors which are found in the cells of the nervous system, the retina of the 
eye, kidneys, gastrointestinal tract, liver, gonads, heart, prostate gland, skin and immune 
system (6). Melatonin receptors, MT1, MT2 and MT3, affect the functioning of ionic chan-
nels, second messenger levels and the expression and activity of many protein enzymes. 
MT1 and MT2 receptors belong to the superfamily of receptors conjugated with G proteins, 
the so-called G-protein-coupled receptors (GPCR), whereas MT3 belongs to the family of 
quinone reductases, but has not been identified in mammals (7). Melatonin may affect a 
number of secondary relays such as cyclic adenosine monophosphate (cAMP), cyclic gua-
nosine monophosphate (cGMP), inositol trisphosphate (IP3), diacylglycerol (DAG) or ara-
chidonic acid (6). Indoleamine can also bind to retinoic acid receptor-related orphan recep-
tor/retinoid Z receptor (ROR/RZR). ROR-α occurs in the central nervous system (CNS), 
brown adipose tissue, liver, testicles and skin, ROR-β mainly in the CNS, ROR-ɣ in skeletal 
muscles (6). These receptors affect the development of CNS and the immune system, regu-
late circadian rhythm and participate in cell differentiation and proliferation. Melatonin 
also affects cells by combining with intracellular proteins, e.g., calmodulin (6, 7).
MELATONIN SYNTHESIS
The synthesis of melatonin begins with hydroxylation of tryptophan followed by 
 decarboxylation with the participation of 5-hydroxytryptophan 5-hydroxylase and 5-hy-
droxytryptophan decarboxylase, which leads to the formation of serotonin (6, 8). Serotonin 
is acetylated by serotonin N-acetyltransferase (NAT) followed by methylation by hydroxy-
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indole-O-methyltransferase (HIOMT). This is how N-acetyl-5-methoxytryptamine, or 
melatonin, is formed. The resulting compound is released into the blood and its half-life is 
about 2–20 min. Melatonin is metabolised in the liver by cytochrome P450 and its metabo-
lites are removed by kidneys. Melatonin metabolites include: 6-hydroxymelatonin, 3-hy-
droxymelatonin, 6-sulfotoximelatonin, cyclic 3-hydroxymelatonin, N1-acetyl-N2-formyl- 
-5-methoxykynuramine (AFMK) and to a lesser extent N1-acetyl-5-methoxykynuramine 
(AMK). In mammals, the biosynthesis of the pineal melatonin is regulated by a superior 
biological clock, located in the suprachiasmatic nucleus of the hypothalamus (SCN) (6–8).
Studies of melatonin in plants have a much shorter history since this substance has 
been identified in plants in 1995 (9). The indolamine synthesis is much higher in plants 
than in animals. Plants synthesize tryptophan via the shikimic acid pathway, and thus the 
ability to synthesize melatonin is not limited by the availability of tryptophan in their 
environment. In plants, tryptophan is first decarboxylated and then hydroxylated, inversely 
to animals. Under normal conditions, the synthesis process takes place in chloroplasts, 
however, when the processes are blocked, then the synthesis pathway takes place in the 
mitochondria (9).
FUNCTIONS OF MELATONIN
Currently, melatonin is used as a sleeping remedy (10). It is used as a supplement and 
as a drug in sleep disorder associated with the change of time zones and shift work, as well 
as in the disturbance of the circadian rhythm of sleep and wakefulness in blind patients. 
Geriatric patients are also increasingly reaching for indoleamine. Many studies confirm 
the beneficial effect of melatonin on various diseases (10). Melatonin works paracrine, auto-
crine, endocrine and has anti-inflammatory activity (2, 10). It regulates circadian rhythm 
and affects reproductive activity in mammals through the secretion of hormones of the 
hypothalamus, pituitary gland and gonads. It regulates the secretion of hormones such as 
prolactin, lutropin, follitropin, somatotropin and adrenocorticotropin. It participates in 
the regulation of the immune system by increasing the activity of NK cells, phagocytes, as 
well as the synthesis of IL-2, IL-6, and IFN-ɣ by mononuclear cells (2). It plays an important 
role in disorders of the digestive system (peptic ulcer, hypersensitive bowel syndrome) and 
affects glucose metabolism (8). It protects the cardiovascular system through changes in 
hypertension thanks to its antioxidant and antilipid properties. There are reports of its 
impact on mental and neurological diseases, due to its neuroprotective effect (8, 11). For 
many years, we have been talking about anticancer and oncostatic properties of melatonin 
that inhibits the activation and proliferation of cancer cells (12, 13). This refers to melanoma, 
glioma, breast cancer, lung, liver, kidney, ovary or bladder cancer. In vitro or in vivo admini-
stration of melatonin results in inhibition of tumor growth and induction of tumor cell 
apoptosis. Melatonin regulates pro-apoptotic and anti-apoptotic factors in normal condi-
tions and during oxidative stress. In addition, studies are suggesting a beneficial effect of 
melatonin on the infant’s colic stitches (14).
Antioxidant effect
Scavenging of reactive oxygen species by melatonin and its metabolites. – The melatonin 
molecule is soluble in water as well as in fats, therefore, it can act as an antioxidant both in 
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the aqueous environment inside the cell and in body fluids, as well as in the cell mem-
branes and cell organelles (9). Melatonin causes a reduction in oxidative stress. It is beli-
eved that its antioxidant effect is much stronger than vitamins E and C, and glutathione. 
The molecule can capture up to 10 ROS (reactive oxygen species) compared to classic anti-
oxidants that neutralize one or less ROS (9). The protective effect of melatonin is to increase 
the activity of antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT) 
and glutathione peroxidase (GPx) by increasing the expression of the above-mentioned 
enzymes (7). Elevated levels of CAT mRNA, SOD and GPx as a result of melatonin were 
observed. In addition, indoleamine reduces the activity of pro-oxidative enzymes such as 
nitric oxide synthase. The best effects were observed in conditions where the hormone 
concentration was physiological or near physiological. Indoleamine increases the activity 
of ɣ-glutamylcysteine synthetase, glutathione reductase and glutathione transferase, 
which participate in the synthesis of glutathione. Additionally, melatonin is located on the 
surface of cell membranes near the polar heads of phospholipids, consequently protecting 
the cell membranes against oxidation. By changing the fluidity of the membranes, it re-
moves radicals before they damage the lipids and proteins of the cell membrane. Melato-
nin has no pro-oxidative properties (7).
Melatonin is a potent radical scavenger and electron donor for highly reactive free 
radicals because it is a molecule rich in electrons (9). It can neutralize species like hydroxyl 
radical, hydrogen peroxide, singlet oxygen, nitric oxide, hypochlorite and peroxyl radical (9). 
The reaction product of melatonin with a hydroxyl radical is 3-hydroxymelatonin  excreted 
in urine (7). Melatonin removes singlet oxygen at a constant rate of 2.2 × 107 L mol–1 s–1 (15). 
This molecule probably does not have the capacity to remove superoxide anion radicals. 
Melatonin combines with a hydroxyl radical to give a compound that combines with the 
superoxide anion radical to form N1-methyl-N2-formyl-5-methoxykynuramine. AFMK 
may undergo a catalytic reaction by catalase and leads to the formation of N1-acetyl-5- 
-methoxykynuramine. The removal of hydrogen peroxide depends on the concentration of 
the hormone and the molecule is converted into AFMK. This process takes place in two 
stages; in the first stage, the reaction rate is constant and amounts to 2.3 × 106 L mol–1 s–1, 
the second stage is much slower. Melatonin removes nitric oxide at a rate of 3.0 × 107 
 L mol–1 s–1 (16).
Metabolites of melatonin also have an antioxidant effect (9). Several studies have 
shown that cyclic 3-hydroxymelatonin is a stronger antioxidant than melatonin itself and 
causes the capture of the hydroxyl radical and other ROS; AMK and AFMK have antioxi-
dant properties as well (9).
Activation of elements of the antioxidant response
One of the latest reports of antioxidative mechanisms of melatonin is its action by 
activating the ARE system, increasing Nrf2 levels and inhibiting NF-κB activity (17). Acti-
vation of elements of the antioxidant response (ARE) leads to the transcription of many 
antioxidant proteins and enzymes that process reactive oxygen species and transport pro-
teins. The nrf2-ARE pathway may stimulate the activity of antioxidant enzymes, such as 
SOD, CAT, GPx, homooxygenase-1 (HO-1), quinone oxidoreductase (NQO1), sulfadoxine 
(Srx), thioredoxin reductase (Txnrd), glutathione S-transferase (GST) (17–19). Activation of 
the Nrf2-ARE pathway contributes to protection against various diseases, i.e., cardiovas-
cular diseases, neurodegenerative diseases (i.e., Alzheimer’s disease, Parkinson’s disease, 
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Huntington’s disease, multiple sclerosis), cancer, but it can also protect cancer cells against 
therapy (19, 20). Melatonin increases Nrf2 levels in cells during oxidative stress (19). Deng 
et al. (21) presented studies in which the action of melatonin is associated with the Nrf2 
transcription factor and its translocation to the nucleus and interaction with ARE. In con-
trast, Ding et al. (22) observed an increase in the concentration of Nrf2 in the nucleus of 
mice subjected to traumatic brain injury, along with the increase in the transcription of 
antioxidant enzymes, i.e., HO-1, NQO1, GPx, SOD. Subsequent studies have shown that 
melatonin alleviates the effects of stress and alcohol consumption by protecting the hippo-
campus of the brain, and regulates the Nrf2/H0-1 path (23). Additionally, melatonin 
 inhibits the activity of NF-κB (19). There is little research on this topic, but it is likely that 
melatonin increases the concentration of IκB-alpha (NF-κB inhibitor). Aparicio et al. (24) 
presented studies on mouse macrophages in which they demonstrated the effect of mela-
tonin on the NF-κB cascade and the Nrf2 pathway. Peritoneal macrophages from mice 
were isolated and treated with melatonin at 12.5, 25, 50 and 100 µmol L–1 in the presence 
or absence of 5 mg mL–1 LPS for 18 h. Melatonin reduced the levels of nitrites, iNOS, COX-2, 
mPGES-1, phosphorylation of p38 MAPK, and prevented the translocation of NF-κB. 
 Melatonin reduces pro-inflammatory mediators and increases expression of HO1 through 
the NF-κB cascade, p38 MAPK and Nrf2 signaling pathways in mouse macrophages. Mela-
tonin has proven to be a promising therapeutic for diseases associated with over-activation 
of macrophages.
MELATONIN – USE AND ANTIOXIDANT PARAMETERS
Animal model
Effect of melatonin on the disease treatment. – Research on animal models is an important 
element in research. Researchers are extensively studying the effects of melatonin in vivo. 
Brazao et al. (25) evaluated the immunological and antioxidant changes caused by aging 
and infection due to Trypanosoma cruzi. Rats infected with T. cruzi and treated with mela-
tonin showed increased activity of SOD and GSH in plasma as well as high levels of CD4+ 
CD28-negative T cells and reduction of CD28-negative in CD4+ and CD8+ T cells. However, 
in subsequent studies on rats with oxidatively damaged thymus, an increase in SOD and 
a decrease in antibodies against the thyrotropin receptor (TRAb) after indoleamine admini-
stration were observed. There was an increase in thymus and an increase in thymocytes. 
Melatonin is shown to be useful in the treatment of Chagas disease. An interesting obser-
vation is also the protection by melatonin in mastitis, consisting of antioxidant and anti-
inflammatory effects.
In many studies with melatonin treatment, a decrease in malondialdehyde (MDA) is 
observed, suggesting protection against lipid peroxidation (26–28). The aqueous buffalo 
was injected subcutaneously with 18 mg melatonin per 50 kg body mass, then blood sam-
ples were taken and analyzed for MDA, NO and total antioxidant capacity (TAC). The 
 results show an increase of TAC, a decrease of MDA, and 90 % induction of estrus in treated 
animals indicating improvement of fertility (26). Another study was presented by Onk et 
al. (29), who evaluated the beneficial effects of melatonin in the treatment of diabetes. Rats 
with induced diabetes by using streptozocin were treated with melatonin at a dose of 20 
mg kg–1 body mass per day. Melatonin reduced the level of MDA and myeloperoxidase 
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(MPO) to a normal level (control group). In addition, decreased expression of cleaved cas-
pase-3 was observed. Higher MDA values after indoleamine treatment were also observed 
in PC (pulmonary circulation) contamination caused by isolated blunt chest trauma in rats. 
Moreover, higher total antioxidants capacity values and reduction of histopathological 
lesions were observed, including protective effects on distant organs, for example, liver 
and kidneys, by reducing oxidative stress (30). Melatonin also reduces the level of MDA 
and increases the activity of SOD and CAT in Chhotanagpuri sheep (31).
Melatonin can be an effective and promising therapeutics in liver diseases including 
ischemia-reperfusion injury (IRI), non-alcoholic fatty liver disease (NAFLD), non-alcoholic 
steatohepatitis (NASH), hepatic fibrosis, hepatic cirrhosis and hepatocellular carcinoma 
(HCC) (32–34). Animal studies have shown a reduction in MDA and an increase in SOD, 
CAT, and GSH in animals treated with melatonin with induced liver damage (32). In con-
trast, Chen et al. (33) demonstrated a decrease in NOX1, NOX2, NF-κB protein expression 
in the liver and an increase of HO-1 NQO-1 protein expression in IRI rats. Kireev et al. (34) 
showed reductions in MDA4-HDA and cytosolic NOx in rats with IRI, as well as increases 
in GPx, GSH/GSSG and GST. The protective role of melatonin in the liver fibrosis was 
demonstrated by Mortezaee et al. (32). They described the reduction of MDA and an 
 increase in SOD, GPx. In addition, subsequent scientists have demonstrated protection 
against cirrhosis by reducing TBARS and increasing SOD, GPx GST and CAT (35). Melato-
nin has strong antioxidant properties that can help restore liver function after ischemia-
reperfusion injury (36). After treatment with melatonin, an increase in the activity of anti-
oxidant enzymes, including SOD and GSH, as well as a decrease in ALT, AST and LDH 
levels were observed.
Indoleamine also has a protective effect on other organs such as the thyroid, larynx, 
kidneys and pancreas (36–41). Melatonin reduces hyperthyroidism induced by oxidative 
stress in hamsters and decreases nerve cell death in the region of the hippocampus of the 
brain. This may be important in cognitive and memory disorders in women with hyper-
thyroidism. A decreased level of TBARS and increased activity of antioxidant enzymes 
was observed (37). Melatonin also protects the pancreas from damage by reducing oxida-
tive stress and increasing the activity of antioxidant enzymes in acute pancreatitis caused 
by cerulein in Wistar rats. Indoleamine prevents lipid peroxidation (decrease of MDA), 
protein oxidation and directly and indirectly can stimulate the expression of antioxidant 
enzymes (38). Melatonin has antioxidant and anti-inflammatory effects in the functioning 
of the kidneys. Ashen et al. (39) described the action of the hormone on kidney damage 
developed after subrenal aortic retention in rats. It was observed that melatonin had a 
beneficial effect on damaged kidneys caused by aluminum and hypertension (40). Subse-
quent research presents a very important aspect nowadays, due to the large population of 
smokers in the world. Smoking causes pathological changes in the mucous membrane of 
the larynx and the development of tumors. Studies in rats have shown that melatonin may, 
to a certain extent, suppress adverse effects, which may be important for smokers (41).
A number of studies on animal models show that melatonin can be used as a thera-
peutic agent in the treatment of brain damage (42, 43). Ischemic areas have been shown to 
decrease significantly after using melatonin. Venezuelan equine encephalitis leads to 
apoptosis and induces an anti-inflammatory response by increasing CD200 expression. 
Mice infected with the above-mentioned virus were tested and increased animal survival 
by 25 %, decreased apoptosis and CD200 expression were observed (42).
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The central nervous system and the brain are susceptible to oxidative stress, which 
can lead to stroke (44). Delivery of antioxidants such as melatonin may prevent the forma-
tion of oxidative stress. Melatonin acts as a scavenger of free radicals and as an indirect 
antioxidant. It removes hydroxyl radicals generated by Fenton’s reaction and reduces lipid 
peroxidation in the brain and also blocks toxicity induced by singlet oxygen. Studies in rats 
with induced stroke and removed pineal glands have shown that the use of melatonin at 
a dose of 5 mg kg–1 at the beginning of reperfusion resulted in an improvement in the 
animals’ condition. There was a decrease in ischemic areas in the gray matter and white 
brain, as well as a reduction in the inflammatory response, reduced brain edema. In addi-
tion, in vitro and in vivo studies show the protective effect of melatonin on glial cells.
Protection against toxic effects of chemical compounds causing oxidative stress. – Melatonin 
protects against the toxic effects of various chemical compounds that cause oxidative 
stress (45–49). One of such compounds is MK-801 which induces oxidation in the prefron-
tal cortex of rats causing psychosis (45). There is also an adverse effect of cadmium on the 
reproductive system in male mice and the mitigation of toxic effects through the use of 
melatonin. A reduced level of MDA, increased SOD activity, GSH and an increase in TNF- 
-alpha and IL-1 beta were observed (46). Another experience shows that melatonin prevents 
damage caused by acrylamide. It soothes lipid peroxidation, contributes to the growth of 
antioxidant enzymes, i.e., SOD, and a lower level of DNA damage in the cerebellum of the 
rat (47). The cerebellum is exposed to various chemical factors that cause loss of neurons 
and organ reduction during development. One of the toxic compounds is lead, which 
causes oxidative stress and neurotoxicity. The effect of melatonin (10 mg kg–1) on lead- 
- induced toxicity in rats was evaluated. A reduction in lipid peroxidation was observed as 
well as the protection of the cerebellum against lead toxicity (48). Subsequent experiments 
have shown that melatonin acts neuroprotective on the cerebellum with the toxic effects 
of ethanol, and reduces the levels of homocysteine (Hcy) in rat plasma (49).
Protection after radiation exposition. – In addition to chemical compounds, animals are 
exposed to various radiations that melatonin can protect against (50, 51). Tropical animals 
are regularly exposed to UV radiation, which is why the protective effect of melatonin on 
Funambulus pennanti, which was exposed to UVB (1.5 J cm–2), was studied. Melatonin could 
bind to the melatonin membrane receptor MT1 and the RORα nuclear receptor. Therefore, 
after treatment with melatonin, the activity of SOD, CAT, GPx increased significantly. 
Melatonin increased the activity of antioxidant enzymes and neutralized free radicals to 
alleviate the damage caused by UVB radiation. UVB radiation indirectly damaged spleen 
tissue, although the organ was not directly exposed to the harmful factor. Splenocytes 
apoptosis was observed, while melatonin was followed by the restoration of homeostasis, 
which consequently prevented the loss of organ function (50). Subsequent studies have 
shown that melatonin acts as an antioxidant on testicles of rats exposed to microwaves by 
reducing oxidative stress and DNA fragmentation (51).
Cell lines
Research on cell lines is the first stage of clinical research. Cell lines are often used in 
survival and apoptosis studies. Eucaryotic lines treatment as well as cancer cell lines treat-
ment by melatonin are still practiced (52–56). Shu et al. (52) investigated the effect of mela-
tonin on induced pluripotent stem cells iPSC [derived from neuronal stem cells (NSCs)] 
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that were exposed to H2O2. The study used 1 µmol L–1 melatonin, 1 µmol L–1 melatonin 
receptor antagonist – luzindole, and 10 µmol L–1 phoshatidylinositide-3 kinases (PI3K) 
inhibitor. The results showed iPSC stimulation with H2O2, improved stabilization of mito-
chondrial membrane potential, and decreased apoptosis rate. Treatment with other sub-
stances (melatonin receptor antagonist – luzindole, PI3K inhibitor) inhibited proliferation. 
Melatonin protects NSCs through melatonin receptors and activation of the PI3K/AKT 
pathway by phosphorylation. This pathway mediates the reduction of cell death and the 
improvement of cell growth and differentiation. In addition, melatonin treatment reduces 
DNA fragmentation, weakens caspase-3 activity, and also improves the Bcl-2/Bax ratio.
Subsequent studies showed the protective effect of indoleamine on SH-SY5Y cells (hu-
man neuroblastoma cell line) on which methamphetamine (METH) was acting (53). Treat-
ment with melatonin also significantly inhibited the induction of retinal pigment epithelium 
(RPE) cell damage caused by H2O2, and decreased apoptosis, increased mitochondrial 
membrane potential and autophagy (54). A reduced Bax/Bcl-2 ratio increased LC3-II and 
Beclin-1 protein expression. Additionally, decreased p62 expression was observed.
Oxidative stress participates in abnormalities in nucleus neural precursor cells (NPC) 
(56). The effect and mechanism of melatonin action on stress-induced oxidative damage to 
NPCs in rats were investigated. Melatonin has preserved the viability of NPC cells under 
oxidative stress. Apoptosis index, ROS and MDA levels decreased, but GSH and SOD acti-
vity increased. Inhibition of the mitochondrial pathway of apoptosis has been observed 
(55). Zhu et al. (56) described the use of melatonin in the prophylaxis of intestinal diseases 
because of its antioxidant capacity. It has been shown to improve immunity to oxidative 
stress of mice with colitis and regulates intestinal bacterial flora.
Melatonin reverses the damage of Ca2+ absorption in some intestinal disorders that 
occur with oxidative stress and apoptosis (57). Apoptosis induced by menadione (MEN) in 
intestinal cells was stopped by melatonin, as indicated by the activity of caspase-3 and the 
retention of DNA fragmentation.
Melatonin treatment strengthens the proliferation of peripheral blood mononuclear 
cells (PBMCs) treated with glucocorticoids (58). Increased dependence of Nrf2/hemeoxygen-
ase-1 (HO-1) and an increase in the Bcl-2/Bax ratio were observed, suggesting that apoptosis 
is stopped. PBMC treated with melatonin increased the expression and activity of MnSOD 
and catalase (59). Sanchez et al. (60) noted that melatonin receptors are present in 661W 
(cone-like photoreceptor cell line) cells. Melatonin can prevent the death of photoreceptor 
cells induced by H2O2 by inhibiting the pro-apoptotic Fas/FasL-caspase-3 pathway.
Studies on cell lines suggest that melatonin inhibits apoptosis by affecting proapo-
totic proteins (Bid, Bad, Bax, etc.) and anti-apoptotic (Bcl-2, Bcl-XL, Bcl-w, etc.), which con-
sequently leads to inhibition of apoptosis pathways (12, 13).
Research on humans
Clinical trials on patients are the last stage before the medicine is allowed for sale. 
Scientific reports suggest that melatonin can be used as a therapeutic in the treatment of 
diseases with free radical etiology (61–65). Melatonin treatment may be beneficial for 
 patients with metabolic syndrome, especially hypertension (61). Koziróg et al. (61) observed 
an increase in CAT activity, a decrease in TBARS, improvement of lipid profile, a decrease 
of LDL-C and a reduction of blood pressure in patients treated with indoloamine. How-
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ever, supplementation with melatonin in obese patients facilitates weight reduction, im-
proves antioxidant defense and regulates the secretion of adipokines (62). An increase in 
adiponectin of omentin-1 and GPx activity was observed. Examinations in obese women 
were also conducted by Alamdari et al. (63). The level of TNF-alpha, IL-6 and MDA had 
decreased, while TAC increased. Diabetes is currently the largest civilization scourge, 
even in children. Administration of melatonin to patients with non-insulin-dependent 
diabetes resulted in a significant increase in the morning concentration of melatonin and 
the activity of SOD1 and also a reduction in the level of MDA (64). Improvement in anti-
oxidant defense has been observed, therefore supplementation of melatonin is suggested 
as an additional treatment to control the complications of diabetes. Oxidative damage was 
suggested as the main cause of aging and the development of age-related diseases, includ-
ing type 2 diabetes (65). The use of melatonin in the elderly at 2 mg and 5 mg per day was 
studied but there were no differences observed at the level of antioxidant enzymes.
Melatonin is tested in the treatment of neurodegenerative diseases as an antioxidant 
and neuroprotective agent (66–69). In patients with multiple sclerosis (MS), melatonin acts 
as an antioxidant and improves the reduced quality of sleep (66). The effect of melatonin on 
the expression of mRNA and sirtuin-1 (SIRT1) activity as well as its impact on superoxide 
dismutase 2 (MnSOD) and catalase activity in peripheral blood mononuclear cells (PBMC) 
in MS and healthy patients was investigated (59). Melatonin increases the activity and level 
of SIRT1 catalase mRNA in ill and healthy patients, whereas MnSOD increases only in 
 patients with MS. A significant correlation was observed between the activity of SIRT1 and 
the catalase activity in PBMC of patients after treatment with melatonin. Melatonin can also 
relieve oxidative stress in neurodegenerative diseases such as Parkinson’s disease (PD) (67). 
In the PD model, increased activity of antioxidant enzymes and plasma homocysteine 
 reduction in plasma was shown due to homocysteine (Hcy PD model). Administration of 
melatonin may alleviate oxidative stress in the neurodegeneration process in the elderly 
(Xeroderma pigmentosum group A, XPA) (69). XPA modulates melatonin metabolism and 
circadian rhythm (68). The beneficial effects of melatonin in patients with Charcot-Marie- 
-Tooth neuropathy (CMT) have also been shown to reduce the hyperoxidation and inflam-
matory state with which the reduction of the degenerative process may be associated (69).
Melatonin may act in a protective and therapeutic way to various diseases, including 
Sickle Cell Syndrome (SCA) (70). The level of melatonin was significantly lower in patients 
with SCA than in the control group. Patients with SCA showed a higher concentration of 
TBARS. Melatonin may in the future be a therapeutic target to improve antioxidant  defense, 
and also to alleviate the symptoms of SCA.
The reported studies demonstrated the potential role of melatonin application against 
diseases of different etiologies (Table I).
Antioxidative action in plants
Melatonin plays a huge role in plant protection (84–106). It acts as an antioxidant and 
a signaling molecule that increases the abiotic resistance to stress in plants (84, 90, 95, 97–
106). It improves the tolerance of plants to heavy metals such as zinc, vanadium, cadmium 
and others. The study analyzed the response of watermelon seedlings to vanadium in a 
dose of 50 mg L–1 using melatonin 0.1 µmol L–1 (84). Higher chlorophyll content, photosyn-
thesis assimilation and plant growth were demonstrated in comparison with melatonin 
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treated plants. Initial treatment with indoloamine reduced vanadium content in leaves and 
shoots by reducing the transport of heavy metal from root to stem. In addition, reduction 
of H2O2 and MDA in watermelon seedlings and enhancement of gene expression for SOD, 
peroxidase, ascorbic peroxidase, glutathione-S-transferase and GPx were also observed. 
Zhang et al. (85) conducted exogenous melatonin testing for browning in lychee after har-
vest. The fruit was treated with an aqueous solution of melatonin (0.4 mmol L–1) and stored 
at 25 °C for 8 days. Melatonin has severely inhibited browning of the pericardium and 
discoloration during storage. It inhibited the production of superoxide radicals, hydrogen 
peroxide, malondialdehyde. This substance delayed the loss of the total content of phenols, 
flavonoids and anthocyanins and enhanced the activity of antioxidant enzymes, i.e., super-
oxide dismutase (SOD), catalase (CAT), ascorbic peroxidase (APx) and glutathione reductase 
(GR), as well as reduced polyphenol oxidase activity (PPO) and peroxidase (POD). Melatonin 
delays the aging of kiwi leaves by activating antioxidant capacity and enhancement of 
flavonoid biosynthesis (86).
Melatonin plays a role in the improvement of germination, maturation, photosynthe-
sis, biomass production, the circadian rhythm of membrane integrity, the development of 
root, leaf senescence, osmoregulation and abiotic stress (salt, drought, cold, heat, oxidation, 
heavy metals) (87). It induces gene expression which helps the plant cope with biotic and 
abiotic stress. The use of melatonin in post-harvest products is a very common material for 
research. Peaches were treated with 0.1 mmol L–1 melatonin and a slowdown in aging, 
increased activity of antioxidant enzymes and ascorbic acid content were observed (87, 88). 
In an abiotic environment in the absence of water deficiency, the addition of 200 µmol L–1 
melatonin resulted in changes in the activity of antioxidant enzymes (89).
The role of exogenous melatonin in the regulation of gene expression in plants is quite 
unknown today (90, 91). The studies showed that melatonin alleviated oxidative stress in 
apple leaves by decreasing the expression of the MdTDC1, MdT5H4, MdAANAT2, MdASMT1 
genes and inhibited membrane damage and lipid peroxidation (90). Melatonin also pro-
tected tomatoes from salinity and heat by increasing the expression of the SlcAPx, SlGR1, 
SlGST, SlPh-GPx genes and activation of the antioxidant enzyme system (91). In turn, the 
indoleamine found in seeds presumably protects the embryo, remaining in a more or less 
dry environment in which the antioxidant enzymes cannot function effectively or be acti-
vated (2). Therefore, the role of a small molecule of melatonin as an effective antioxidant 
becomes important and is confirmed by its high content in herbs and other plants of the 
Alpine and Mediterranean region. These plants, exposed to extreme temperatures and UV 
radiation of considerable intensity, may use antioxidant properties (activation of the anti-
oxidant enzyme system or elimination of ROS) to protect against damage caused by these 
factors. In addition, melatonin protects cucumber seeds and young seedlings from oxidative 
stress, by directly and indirectly detoxifying ROS, thanks to which plants grow better even 
in a harmful environment (92). Indoleamine causes the inhibition of leaf aging caused by 
darkness. This may be due to ROS uptake by activating the enzymatic antioxidative path-
way catalyzed by SOD and reducing chlorophyll degradation (93). Melatonin relieves stress 
caused by the cold that caused oxidative stress by increasing ROS accumulation and reduc-
ing photosynthesis in tea leaves of Camellia sinensis L. Indoleamine reduced oxidative stress, 
strengthened the antioxidant potential and redox homeostasis, which as a consequence 
contributed to mitigating the adverse effect of cold on tea plants (94).
Table II presents recent research describing the effects of melatonin on the plants.
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CONCLUSIONS
Melatonin is a widespread molecule that performs many functions in the body. It exhi-
bits strong antioxidant properties in cell lines, animal models and humans, by activating 
antioxidant enzymes such as SOD, CAT, GPx. It protects cells from lipid peroxidation by 
reducing MDA and decreasing TBARS. Additionally, it neutralizes ROS and combats oxida-
tive stress. Its antioxidant mechanisms are not thoroughly understood. As of today, it is 
known that melatonin works via melatonin receptors, nuclear receptors, directly with cyto-
plasmic proteins and activates the Nrf2-ARE pathway, and also affects NF-κB. Indoleamine 
is not indifferent to the processes of apoptosis, where it plays an enormous role in the path-
ways through changes in pro-apoptotic and anti-apoptotic proteins, in particular the Bcl2/
Bax ratio, which may be important in the antioxidative process. Thanks to its antioxidant 
properties, melatonin can be successfully used in the treatment of diseases with free radical 
etiology, neurodegenerative diseases (Parkinson’s disease, Alzheimer’s disease, multiple 
sclerosis), diabetes, cardiovascular diseases, stroke, as well as cancers. Melatonin is unique 
in comparison to other signaling molecules not only due to the prevalence and variety of 
mechanisms involved in the transmission of the signal carried by it but also due to its anti-
oxidant activity. Therefore, it is important to continue research on this amazing hormone in 
terms of antioxidant mechanisms and its use in the treatment of various diseases.
Abbreviations, acronyms, symbols. – AFMK – N1-acetyl-N2-formyl-5-methoxykynuramine; ALT – 
alanine aminotransferase; AMK – N1-acetyl-5-methoxykynuramine; ARE – elements of the antioxidant 
response; AST – aspartate aminotransferase; cAMP – cyclic adenosine monophosphate; CAT – catalase; 
cGMP – cyclic guanosine monophosphate; CNS – central nervous system; COX-2 – cyclo oxygenase-2; 
DAG – diacylglycerol; DNA – deoxyribonucleic acid; GPCR – G-protein-coupled receptors; GPx – 
 glutathione peroxidase; GSH – glutathione (reduced form); GSSG – glutathione (oxidized form); GST – 
glutathione S-transferase; Hcy – homocysteine; 4HDA – 4-hydroxyalkenals; HIOMT – hydroxyindole- 
-O-methyl transferase; HO-1 – homooxygenase-1; IFN-ɣ –  gamma interferon; IL – interleukin; iNOS 
– inducible nitric oxide synthase; IP3 – inositol trisphosphate; IRI – ischemia-reperfusion injury; IκB-
alpha – nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; LDH – lac-
tate dehydrogenase; MAPK – mitogen-activated protein kinase; MDA – malondialdehyde; MK–801 – 
dizocilpine; MnSOD – superoxide dismutase 2 [SOD 2]; mPGES1 – microsomal prostaglandin E 
synthase-1; MPO – myeloperoxidase; mRNA – messenger RNA (ribonucleic acid); MS – multiple scle-
rosis; NAFLD – non-alcoholic fatty liver disease; NASH – non-alcoholic steatohepatitis; NAT – N-acetyl-
transferase; NF-κB – nuclear factor kappa-light-chain-enhancer of activated B cells; NK cells – natural 
killer cells; NPC – neural precursor cells; NQO1 – NAD(P)H quinone dehydrogenase 1; NQO1 – qui-
none oxidoreductase; Nrf2 – nuclear factor erythroid 2-related factor 2; NSCs – neuronal stem cells; 
P13K – phoshatidylinositide-3 kinase; PBMCs – peripheral blood mononuclear cells; POD – peroxidase; 
PPO – polyphenol oxidase activity; ROR/RZR – retinoic acid receptor-related orphan receptor/retinoid 
Z receptor; ROS – reactive oxygen species; SCA – sickle cell syndrome; SCN – suprachiasmatic nucle-
us of the hypothalamus; SIRT1 – sirtuin-1; SOD – superoxide dismutase; SOD1 – superoxide dismutase 
1 [Cu-ZnSOD]; Srx – sulfedoxine; TAC – total antioxidant capacity; TBARS – thiobarbituric acid reactive 
substances; TRAb – antibodies against the thyrotropin receptor; Txnrd – thioredoxin reductase
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